Substance / Medication

Hemin

Overview

Active Ingredient
hemin
RxNorm CUI
5175

Indications

PANHEMATIN is a hemin for injection indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after initial carbohydrate therapy is known or suspected to be inadequate. Limitations of Use • 2.1 [See Dosage and Administration ()] Before administering PANHEMATIN, consider an appropriate period of carbohydrate loading (i.e., 400 g glucose/day for 1 to 2 days). • Attacks of porphyria may progress to a point whe

Labeler: Recordati Rare Diseases, Inc.Updated: 2025-09-18T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

PANHEMATIN is contraindicated in patients with known hypersensitivity to this drug.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Effects of Repetitive Transcranial Magnetic Stimulation on Poststroke Hemineglect: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Yang Fu-An, Lin Chueh-Ho, Chung Hung-Ning et al. · Neurorehabil Neural Repair · 2025
PMID: 39727289Meta-Analysis
Heminephrectomy in Adults: A Systematic Review with Cumulative Analysis.
Clement Keiran, Hendry Jane, Keeley Francis X et al. · Urol Int · 2018
PMID: 29224026Meta-Analysis
"Sequential multimodality stimulation" for post-stroke-hemineglect: Feasibility and outcome in a pilot randomized controlled trial.
Sukumaran Sajith, Sivadasan Sesh, Sakunthala Parthan T et al. · J Clin Neurosci · 2020
PMID: 31495658RCT
[Constraint-induced movement therapy in the rehabilitation of hemineglect after a stroke].
Marándola M M, Jiménez-Martín I, Rodríguez-Yáñez M et al. · Rev Neurol · 2020
PMID: 32043533RCT
Effects of a robot intervention on visuospatial hemineglect in postacute stroke patients: a randomized controlled trial.
Karner Susanne, Stenner Hanna, Spate Melanie et al. · Clin Rehabil · 2019
PMID: 31409126RCT
Effects of hemin on heme oxygenase-1, gastric emptying, and symptoms in diabetic gastroparesis.
Bharucha A E, Daley S L, Low P A et al. · Neurogastroenterol Motil · 2016
PMID: 27283929RCTFull text (PMC)
Left-hand somatosensory stimulation combined with visual scanning training in rehabilitation for post-stroke hemineglect: a randomised, double-blind study.
Polanowska Katarzyna, Seniów Joanna, Paprot Ewa et al. · Neuropsychol Rehabil · 2009
PMID: 18663642RCT
Healing of gingival recessions using a collagen membrane with a hemineralized xenograft: a randomized controlled clinical trial.
Cardaropoli Daniele, Cardaropoli Giuseppe · Int J Periodontics Restorative Dent · 2009
PMID: 19244883RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Hemin (substance)
SNOMED CT
27345002
UMLS CUI
C0018988
RxNorm CUI
5175
Labeler
Recordati Rare Diseases, Inc.

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.